Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Bioanalysis|August 14, 2015
6th Japan Bioanalysis Forum Symposium: challenge of regulated bioanalysisHarue IgarashiJournal of Separation Science|May 20, 2011
A highly sensitive LC-MS/MS method capable of simultaneously quantitating celiprolol and atenolol in human plasma for a cassette cold-microdosing studyYoshiyuki Minamide, Yukio Osawa, Hiroshi Nishida, et al.Clinical Pharmacology in Drug Development|May 4, 2016
Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteersHiroko Ino, Naoki Takahashi, Takumi Terao, et al.Clinical Pharmacology in Drug Development|October 11, 2018
Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese SubjectsHiroko Ino, Robert Wilson, Takumi Terao, et al.Clinical Pharmacology in Drug Development|December 18, 2018
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese SubjectsHiroko Ino, Yohei Doi, Lia Liefaard, et al.Clinical Pharmacology in Drug Development|January 18, 2020
Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European AncestryTakayuki Iida, Romina A Nand, Hiroko Ino, et al.Bioanalysis|September 11, 2018
The ninth Japan Bioanalysis Forum symposiumJunji Komaba, Jun Hosogi, Harue Igarashi, et al.The AAPS Journal|January 30, 2016
Sample Management: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization TeamMichael J Redrup, Harue Igarashi, Jay Schaefgen, et al.European Journal of Drug Metabolism and Pharmacokinetics|November 9, 2020
Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese SubjectsDebra J Tompson, Carwyn Davies, Nicola E Scott, et al.Bioanalysis|September 14, 2021
Analytical method validation for biomarkers as a drug development tool: points to considerYoshiaki Ohtsu, Seiji Tanaka, Harue Igarashi, et al.Pageof 2